Dana P. Goldman is the Leonard D. Schaeffer Chair and a Distinguished Professor of Public Policy, Pharmacy, and Economics at the University of Southern California. He also directs the USC Schaeffer Center for Health Policy and Economics, a research hub for one of the nation’s premier health policy and management programs in the Sol Price School of Public Policy and USC School of Pharmacy. He is an elected member of the National Academy of Medicine and the National Academy of Social Insurance – two of his field’s highest honors. He is the author of more than 300 articles and book chapters, and his research has been published in leading medical, economic, health policy, and statistics journals. His research has been continuously funded by many public and private sources— including more than $50 million from the National Institutes of Health.
Professor Goldman has served as a formal health policy advisor to the Congressional Budget Office, Covered California, and the Fred Hutchinson Cancer Institute—as well as informally for many private companies and government officials. He serves on the editorial boards of Health Affairs and the American Journal of Managed Care and is founding editor of the Forum for Health Economics and Policy. His work has been featured in the New York Times, Wall Street Journal, Washington Post, The Economist, NBC Nightly News and other media. He is former director of ISPOR and ASHEcon. Dr. Goldman received his B.A. summa cum laude from Cornell University and a Ph.D. in Economics from Stanford University.
Areas of Expertise (6)
health technology assessment
Health Care Reform
Health Policy and Economics
USC Associates Award for Creativity in Research
2017 - Associates awards are “the highest honors the university faculty can bestow on its members for distinguished intellectual and artistic achievements.”
Stanford University: Ph.D., Economics
Cornell University: B.A.
Summa cum laude
- Elected member, National Academy of Medicine
- Elected member, National Academy of Social Insurance
Selected Media Appearances (6)
Op-eds, media appearances and commentary
Dr. Goldman's work has been featured in the New York Times, Wall Street Journal, Forbes, Washington Post, Business Week, U.S. News and World Report, The Economist, NBC Nightly News, CNN, National Public Radio, and other media.
Opinion: This is a health-care plan both Republicans and Democrats should agree onq
The one area of agreement in the debate over health insurance is that too many Americans lack it — now 27 million and counting. The differences emerge over how to expand coverage and how to pay for it.
Here's how we can control drug costs while spurring innovation
The Hill online
Health care is one of the most valuable services that Americans spend their money on, but it also can be the most expensive. Political pressure to do something is enormous. Given the partisan slow boat in Washington, states have started to move with willingness — especially with regard to prescription drugs. This is posing a huge challenge to a rational national policy.
Opinion: Health Care's Killer App: Life Insurance
Wall Street Journal print
The industry could profit by helping policyholders pay for cancer treatments that prolong life.
Opinion: The bigger message behind Amgen’s decision to slash cost of its Repatha cholesterol drug
Amgen has just announced a 60% cut in the price of its innovative anti-cholesterol medicine, Repatha. That is big news to people at risk for heart attacks and strokes, many of whom had been forgoing the treatment because of high out-of-pocket costs.
Opinion: When we find a cure, price it like Netflix to ensure access
The Hill online
An essential lesson from the successful fight against AIDS is that early access to effective treatment can avoid long-term costs.
Research Grants (5)
Roybal Center for Health Policy Simulation
National Institute on Aging $2,176,534
Transforming Research and Clinical Knowledge in Traumatic Brain Injury II
Resource Center for Minority Aging Research
National Institutes of Health $2,345,183
Technological Innovation in Health Care and the Long-Term Outlook
National Institutes of Health $242,971
An Economic and Behavioral Evaluation of Medicare Part D
National Institute on Aging $1,931,757
Selected Articles (6)
Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017Value in Health
2019 The prices of newly approved cancer drugs have risen over the past decades. A key policy question is whether the clinical gains offered by these drugs in treating specific cancer indications justify the price increases.
Insulin Access and Affordability Working Group: Conclusions and RecommendationsAmerican Diabetes Association
2018 There are more than 30 million Americans with diabetes, a disease that costs the U.S. more than $327 billion per year (1,2). Achieving glycemic control and controlling cardiovascular risk factors have been conclusively shown to reduce diabetes complications, comorbidities, and mortality.
Encouraging New Uses for Old DrugsJAMA Network
2017 US Food and Drug Administration (FDA) approval of a new drug typically coincides with a period of patent protection, during which the manufacturer will often apply for additional indications to expand the market for the product. For example, the tyrosine kinase inhibitor imatinib (Gleevec; Novartis) was originally approved to treat Philadelphia chromosome–positive chronic myelogenous leukemia, but has since been approved for treatment of other cancers.
Prescription Drug Cost SharingJAMA Network
2017 Prescription drugs are instrumental to managing and preventing chronic disease. Recent changes in US prescription drug cost sharing could affect access to them.
Substantial Health And Economic Returns From Delayed Aging May Warrant A New Focus For Medical ResearchHealth Affairs
2013 Recent scientific advances suggest that slowing the aging process (senescence) is now a realistic goal. Yet most medical research remains focused on combating individual diseases. Using the Future Elderly Model—a microsimulation of the future health and spending of older Americans—we compared optimistic “disease specific” scenarios with a hypothetical “delayed aging” scenario in terms of the scenarios’ impact on longevity, disability, and major entitlement program costs.
Drug Licenses: A New Model For Pharmaceutical PricingHealth Affairs
2008 High drug prices are a major barrier to patients’ access to drugs and compliance with treatment. Yet low drug prices are often argued to provide inadequate incentives for innovation.